BioTelemetry Inc

Find Ratings Reports
BEAT : NASDAQ : Health Care
$17.81 | %
Today's Range: 17.80 - 18.23
Avg. Daily Volume: 330,900
07/22/16 - 4:00 PM ET

Financial Analysis


BIOTELEMETRY INC's gross profit margin for the first quarter of its fiscal year 2016 has increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. BIOTELEMETRY INC has strong liquidity. Currently, the Quick Ratio is 1.95 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 25.92% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)48.6443.44
EBITDA ($mil)8.223.65
EBIT ($mil)4.950.7
Net Income ($mil)3.97-0.07


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)22.8412.29
Total Assets ($mil)128.93117.16
Total Debt ($mil)23.2424.79
Equity ($mil)80.6664.05


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin68.2962.79
EBITDA Margin16.898.41
Operating Margin10.181.61
Sales Turnover1.421.48
Return on Assets8.89-4.89
Return on Equity14.21-8.96
Debt Q1 FY16 Q1 FY15
Current Ratio2.131.54
Debt/Capital0.220.28
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)27.6427.23
Div / share0.00.0
EPS0.140.0
Book value / share2.922.35
Institutional Own % n/a n/a
Avg Daily Volume327121.0164030.0

Valuation


BUY. BIOTELEMETRY INC's P/E ratio indicates a significant premium compared to an average of 21.90 for the Health Care Providers & Services industry and a significant premium compared to the S&P 500 average of 25.05. For additional comparison, its price-to-book ratio of 6.20 indicates a significant premium versus the S&P 500 average of 2.81 and a significant premium versus the industry average of 3.34. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, BIOTELEMETRY INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BEAT 45.25 Peers 21.90   BEAT 18.26 Peers 12.23

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

BEAT is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

BEAT is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BEAT 23.21 Peers 16.46   BEAT 0.27 Peers 0.95

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

BEAT is trading at a significant premium to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BEAT trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BEAT 6.20 Peers 3.34   BEAT 290.47 Peers 22.01

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

BEAT is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

BEAT is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BEAT 2.72 Peers 0.81   BEAT 6.28 Peers 14.30

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BEAT is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BEAT significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades